9 unknown. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Unknown 9 |
Follow Hypertriglyceridemia: new trials by email Literature Review of Hypertriglyceridemia trials Research Report on Hypertriglyceridemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes EPAVasc, Corn Oil - Diabetes Type 2, Hypertriglyceridemia | Phase 4 | Unknown | University of Ioannina | 450 | 2023-12-01 | 2023-11-15 |
| Insulin and Standard Management in Hypertriglyceridemic Acute Pancreatitis insulin, standard treatment - Hypertriglyceridemia, Acute Pancreatitis | Phase 4 | Unknown | University Medical Centre Ljubljana | 30 | 2022-11-01 | 2022-11-01 |
| Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis. Insulin, plasmapheresis - Acute Pancreatitis, Hypertriglyceridemia | Phase 4 | Unknown | First Affiliated Hospital of Wenzhou Medical University | 200 | 2018-06-06 | 2018-06-06 |
| Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis Insulin, Aphesis - Pancreatitis, Acute, Hypertriglyceridemia | Phase 4 | Unknown | Peking Union Medical College Hospital | 220 | 2017-11-01 | 2017-11-17 |
| Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome Fenofibrate, Simvastatin - Acute Coronary Syndrome, Diabetes Mellitus, Type 2 | Phase 4 | Unknown | Koval' O., MD | 60 | 2014-01-01 | 2016-08-04 |
| Lovaza Mechanisms of Action Omega 3 fatty acid (Lovaza) - Moderate Hypertriglyceridemia. | Phase 4 | Unknown | Brigham and Women's Hospital | 40 | 2012-08-01 | 2013-02-25 |
| Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia DHA-EPA, Ciprofibrate - Hypertension, Hypertriglyceridemia | Phase 4 | Unknown | Hospital Universitario Pedro Ernesto | 52 | 2011-05-01 | 2011-11-29 |
| The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients Omega-3 acid 4 grams per day, Placebo control - Diabetes Mellitus, Type 2, Hypercholesterolemia | Phase 4 | Unknown | Inje University | 70 | 2009-07-01 | 2009-08-06 |
| Triglyceride Lowering Study Omega-3-Acid Ethyl Esters - Hypertriglyceridemia | Phase 4 | Unknown | Jewish Hospital, Cincinnati, Ohio | 25 | 2009-07-01 | 2009-07-08 |
Diabetes Mellitus, Type 2 (3) · Pancreatitis (3) · Diabetes Mellitus (2) · Insulin Resistance (2) · Acute Coronary Syndrome (1) · Coronary Artery Disease (1) · Hypercholesterolemia (1) · Hyperlipoproteinemia Type IV (1) · Hypertension (1) · Inflammation (1) · Thrombosis (1)
Dyslipidemias (9) · Hyperlipidemias (9) · Lipid Metabolism Disorders (9) · Metabolic Diseases (9) · Nutritional and Metabolic Diseases (9) · Glucose Metabolism Disorders (5) · Cardiovascular Diseases (3) · Digestive System Diseases (3) · Endocrine System Diseases (3) · Pancreatic Diseases (3) · Vascular Diseases (3) · Heart Diseases (2) · Hyperinsulinism (2) · Myocardial Ischemia (2) · Arterial Occlusive Diseases (1)
Insulin (3) · Omacor (3) · Corn Oil (1) · Fatty Acids, Omega-3 (1) · Fenofibrate (1) · Plasmapheresis (1) · Simvastatin (1) · ciprofibrate (1)
Brigham and Women's Hospital (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Hospital Universitario Pedro Ernesto (1) · Inje University (1) · Jewish Hospital, Cincinnati, Ohio (1) · Koval' O., MD (1) · Peking Union Medical College Hospital (1) · University Medical Centre Ljubljana (1) · University of Ioannina (1)
United States (2) · Brazil (1) · Greece (1) · South Korea (1) · Ukraine (1)
Charles Glueck, MD (1) · Fernanda J Medeiros, PhD (1) · Jeong H Park, M.D., Ph.D. (1) · Jonathan Brown, MD (1) · Jorge Plutzky, MD (1) · Marcela A Casanova, MSc (1) · Mario F Neves, MD, PhD (1) · Meng-Tao Zhou, M.D. (1) · Olena A Koval', MD, PhD (1) · Wille Oigman, MD, PhD (1)